Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging
- PMID: 14972466
- DOI: 10.1016/j.urology.2003.09.060
Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging
Abstract
Objectives: To examine the relationship of insulin, glucose, and anthropometry with the subsequent risk of prostate cancer.
Methods: The relative risk of prostate cancer by insulin, glucose, and anthropometric measures was evaluated in 823 male participants (87 patients with prostate cancer in 10,737 person-years of follow-up) of the Baltimore Longitudinal Study of Aging who had at least one fasting plasma insulin measurement, which was prediagnostic for those with prostate cancer. Age-adjusted and multivariate-adjusted relative risks were estimated from Cox proportional hazards regression models.
Results: Insulin concentrations were in the normal range (defined as less than 20 microU/mL) for 95.1% of participants. Fasting insulin and glucose levels were unrelated to prostate cancer risk in our overall analysis (P for trend = 0.56 and 0.45, respectively). The relative risk of prostate cancer for the second through fourth quartiles of the waist/hip ratio compared with the lowest quartile was 2.10, 1.96, and 2.06, respectively (P for trend = 0.32). Risk was unrelated to waist circumference and body mass index.
Conclusions: The results of this study do not conclusively support positive associations of markers of insulin and glucose metabolism and obesity with prostate cancer. Additional larger prospective studies with repeated measure of these parameters are warranted to explore these associations further.
Similar articles
-
Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer.Nutrition. 2005 Jun;21(6):686-90. doi: 10.1016/j.nut.2004.11.012. Nutrition. 2005. PMID: 15925292
-
Glycemic status and risk of prostate cancer.Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):628-35. doi: 10.1158/1055-9965.EPI-07-2610. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18349280
-
Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging.Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):390-6. doi: 10.1158/1055-9965.EPI-04-0532. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15734963
-
[Constitutional risk factors in prostate cancer].Actas Urol Esp. 2011 May;35(5):282-8. doi: 10.1016/j.acuro.2010.12.009. Epub 2011 Mar 24. Actas Urol Esp. 2011. PMID: 21435741 Review. Spanish.
-
Fasting blood glucose and risk of prostate cancer: A systematic review and meta-analysis of dose-response.Diabetes Metab. 2018 Sep;44(4):320-327. doi: 10.1016/j.diabet.2017.09.004. Epub 2017 Oct 24. Diabetes Metab. 2018. PMID: 29074328
Cited by
-
Insulin resistance and hyperinsulinaemia in the development and progression of cancer.Clin Sci (Lond). 2009 Nov 23;118(5):315-32. doi: 10.1042/CS20090399. Clin Sci (Lond). 2009. PMID: 19922415 Free PMC article. Review.
-
Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.Br J Cancer. 2011 Mar 1;104(5):875-81. doi: 10.1038/sj.bjc.6606066. Epub 2011 Jan 25. Br J Cancer. 2011. PMID: 21266978 Free PMC article.
-
Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.Cancer Metastasis Rev. 2014 Sep;33(2-3):527-43. doi: 10.1007/s10555-013-9484-y. Cancer Metastasis Rev. 2014. PMID: 24398857 Free PMC article. Review.
-
Urological aspects of the metabolic syndrome.Nat Rev Urol. 2011 Aug 2;8(9):483-94. doi: 10.1038/nrurol.2011.112. Nat Rev Urol. 2011. PMID: 21811224 Review.
-
The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes.Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):2088-96. doi: 10.1158/1055-9965.EPI-10-0112. Epub 2010 Jul 20. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20647401 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical